Back to Journals » Journal of Pain Research » Volume 12

The Statistical Analyses Of The Study “Sufentanil Sublingual Tablet System (SSTS) For The Management Of Postoperative Pain After Major Abdominal And Gynecological Surgery Within An ERAS Protocol: An Observational Study” [Response To Letter]

Authors Turi S , Deni F, Lombardi G , Marmiere M , Nisi FG, Beretta L

Received 13 September 2019

Accepted for publication 13 September 2019

Published 3 October 2019 Volume 2019:12 Pages 2815—2816

DOI https://doi.org/10.2147/JPR.S230945



Stefano Turi, Francesco Deni, Gaetano Lombardi, Marilena Marmiere, Francesco Giuseppe Nisi, Luigi Beretta

Dipartimento di Anestesia, Ospedale San Raffaele, Milano, Italy

Correspondence: Stefano Turi
Department of Anesthesiology, Vita-Salute, University, San Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy
Tel + 39 02 2 643 2656
Email [email protected]

 

We thank Wang and Miao1 for their interest in our recent publication2 and the appreciation of our work. We agree with them on the need of using repeated-measures analysis to evaluate pain intensity at different timepoints. We acknowledge that, for the sake of brevity, our manuscript did not properly clarify the statistical methods used for the analysis and we take this opportunity to better explain them. We performed a repeated measure analysis of variance (ANOVA) to compare pain intensity on different time points. The analysis resulted statistically significant (p<0.01). Afterwards, we performed multiple comparisons using the error deriving from the ANOVA for repeated measures, which turned out statistically significant (p<0.01). In addition, we used the paired t-test to compare pain intensity on day 0 (baseline) and day 3, as indicated in the recent publication (median NRS 6 to 0, p<0.01).2

 

View the original paper by Turi at al and colleagues

This is in response to the Letter to the Editor

Dear editor

We thank Wang and Miao1 for their interest in our recent publication2 and the appreciation of our work.

We agree with them on the need of using repeated-measures analysis to evaluate pain intensity at different timepoints.

We acknowledge that, for the sake of brevity, our manuscript did not properly clarify the statistical methods used for the analysis and we take this opportunity to better explain them.

We performed a repeated measure analysis of variance (ANOVA) to compare pain intensity on different time points. The analysis resulted statistically significant (p<0.01). Afterwards, we performed multiple comparisons using the error deriving from the ANOVA for repeated measures, which turned out statistically significant (p<0.01).

In addition, we used the paired t-test to compare pain intensity on day 0 (baseline) and day 3, as indicated in the recent publication (median NRS 6 to 0, p<0.01).2

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Wang X, Miao S. The statistical analyses of the study “Sufentanil Sublingual Tablet System (SSTS) for the management of postoperative pain after major abdominal and gynecological surgery within an ERAS protocol: an observational study”[Letter]. J Pain Res. 2019;12:2723–2724. doi:10.2147/JPR.S228372

2. Turi S, Deni F, Lombardi G, Marmiere M, Nisi FG, Beretta L. Sufentanil Sublingual Tablet System (SSTS) for the management of postoperative pain after major abdominal and gynecological surgery within an ERAS protocol: an observational study. J Pain Res. 2019;12:2313–2319. doi:10.2147/JPR.S214600

Creative Commons License © 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.